Aim-To analyse the pathogenic mechanism of HIV related thrombocytopenia. Methods-Forty one patients with thrombocytopenia and HIV-1 infection were investigated over two years. Anticardiolipin antibodies were measured using an enzyme linked inmunosorbent assay and antiplatelet antibodies were measured using an immunocapture technique. Tests for VDRL, C3 and C4, antinuclear antibodies and rheumatoid factor were also carried out in all patients and 80 control subjects (HIV-1 positive but non-thrombocytopenic). Indiumoxine labelled platelets were transfused in 13 patients. P24 antigen were also measured in 12 bone marrow aspirates. Results-Antiplatelet antibodies and circulating immune complexes were found exclusively in the thrombocytopenic group; values for antiplatelet antibodies and circulating immune complexes were both higher in homosexual and bisexual patients. Three kinds of pattern were observed using 111 In-labelled platelets: splenic (n = 10); hepatic (n = 2); and destruction of bone marrow in just one case. The two most influential factors in the sequestration pattern were antiplatelet antibodies in the splenic uptake and circulating immune com-
and antiplatelet antibodies were measured using an immunocapture technique. Tests for VDRL, C3 and C4, antinuclear antibodies and rheumatoid factor were also carried out in all patients and 80 control subjects (HIV-1 positive but non-thrombocytopenic). Indiumoxine labelled platelets were transfused in 13 patients. P24 antigen were also measured in 12 bone marrow aspirates. Results-Antiplatelet antibodies and circulating immune complexes were found exclusively in the thrombocytopenic group; values for antiplatelet antibodies and circulating immune complexes were both higher in homosexual and bisexual patients. Three kinds of pattern were observed using 111 In-labelled platelets: splenic (n = 10); hepatic (n = 2); and destruction of bone marrow After 24 hours, scintigraphic images were obtained using a gamma camera. We investigated three areas: the spleen; the liver; and the thorax-sternum (bone marrow activity). 15 Finally, to detect HIV-1 infection in megakaryocytes, specific monoclonal antibodies were used against p24 antigen (Chemicom, USA). The study was carried out on 12 biopsy specimens of bone marrow fixed in B5 and paraffin wax, using the avidin biotin alkaline phosphatase technique. The technique had already been applied to samples of lymph nodes from six patients with AIDS (the presence of p24 antigen in endothelial cells, macrophages, and B lymphocytes was observed). To avoid the possibility of false positive results, the same technique was also applied to six samples of bone marrow from HIV negative patients belonging to no behavioural risk group, and here the test did not give any positive result.
The data processing and analysis were carried out on a IBM compatible computer. The graphics were produced with the Harvard Graphics program (Software Publishing Corporation, Mountain View, California USA). The (table 3) . Table 4 gives details of the patients who were subjected to a gamma camera study to detect the areas of greatest platelet destruction. Three main patterns were observed: (1) splenic (n = 10); one patient (case 10) also showed increased hepatic uptake; (2) hepatic (n = 2) (cases 9 and 11): both showed simultaneous increases in uptake in bone marrow; The differences were not significant. Karpatkin'6 have suggested that anti-idiotype antibodies anti-HIV antibodies or antibodies to unknown platelet antigens might be responsible.
We compared the findings in thrombocytopenic patients with those found in HIV-1 positive but non-thrombocytopenic patients. Antiplatelet antibodies and circulating immune complexes were exclusive to the thrombocytopenic group (56 and 31%, respectively). The rest of the analysed variables did not show any significant differences between the thrombocytopenic and the nonthrombocytopenic patients.
The presence of antiplatelet antibodies could be related to a secondary immune alteration caused by an increase in the polyclonal activity of B lymphocytes caused by HIV. This would stimulate the production of crossreacting antibodies,'7 autoantibodies, and antibodies as opposed to viral adsorbed antigens or any other unknown antigens. The discovery of circulating immune complexes in HIV related thrombocytopenia coincides with what has been described in classic secondary thrombocytopenias (drugs or other viral infections).'8 Antiplatelet antibodies and circulating immune complexes were more common in the homosexual and bisexual men than in the drug misusers, though circulating immune complexes were significantly greater (p < 0 05) in the former group (80%) than in the drug misuser group (23%). Our Thrombocytopenia is probably produced by a combination of marrow destruction, with subsequent ineffective production of, and a decrease in, the number of circulating platelets due to the sequestration and destruction caused by some of the peripheral organs of the mononuclear phagocytic system.2' Kinetic studies of 11 In in patients with classic ITP show three kinds of pattern: Dominguez, Gamallo. Garcia, Lopez-Pastor, Pena, Vazquez destruction in the spleen, the liver, and bone marrow.'524 These patterns were also observed in our study. The significant increase in the destructive activity of the spleen in HIV positive patients was interesting and was considerably greater than in patients with classic ITP. This could explain the excellent results obtained by removing the spleen of these patients, although opinions vary as to the correlation between the results of the 11 In labelled platelet studies and the therapeutic response.'3 15 Nearly all of the patients had a low platelet recovery, which shows a rapid decrease in transfused platelets as a result of peripheral destruction.'5 Measurable differences (p < 001) were only found in patients with less than 200 x 106 CD4/1 lymphocytes who showed a recovery of 53% (practically normal) compared with 28% (decreased) in the others. In fact, patients from the IV-E group, with a better immunological state, showed, during the whole study, a lower platelet count than those from the IV-Cl group, with a low CD4 count and a possible macrophagic disorder, which might explain why peripheral destruction was not so great in these patients.
There were no differences in clinical bleeding or platelet count among the behavioural risk groups, but we found important differences in the presence of antiplatelet antibodies or circulating immune complexes. There was an increase in splenic uptake for antiplatelet antibody positive patients and in hepatic and marrow uptake for circulating immune complex positive patients. The exact cause for the presence of circulating immune complexes or antiplatelet antibodies which influences the kind of sequestration pattern is not known. A possible explanation could be the existence of a different platelet "affinity" in the different sequestration levels. Liver and bone marrow, with cells containing receptors for IgM and C3, probably have a more important role in the elimination of platelets in patients whose platelets have circulating immune complexes bound on to the surface, 26 But these studies were done in vitro. As far as we are aware there is no in vivo evidence for this as yet.
To detect the presence of p24 antigen, and therefore HIV, in the bone marrow we used a monoclonal antibody technique that has previously been used to detect such antigens in the lymphocytes of the lymph nodes or other cells-for example in the intestine.27 Although only 12 patients were studied, we managed to prove that megakaryocytes were infected with HIV-1, by detecting p24 antigen in cytoplasm and the membrane. There was no direct correlation between the presence of p24 antigen in blood and the presence or absence of antiplatelet antibodies or circulating immune complexes.
Infection of the megakaryocytes could produce, in some patients, ineffective autoimmune thrombopoiesis similar to that which occurs in classic ITP,28 or it could produce a maturative and functional change as a result of direct infection by the virus. The primary mechanism of the virus could be the following: HIV-1 induces the production of thrombopoiesis inhibitors or penetrates megakaryocytes through a receptor that has as yet not been identified. This receptor could be CD4,25 another unidentified antigen, or could even be introduced by the circulating immune complexes and used as a "key" through the Fc receptor. The last mechanism has been seen in other virus infections,'6 but obviously it is not unique as not all the patients showing p24 antigen in megakaryocytes were positive for circulating immune complexes.
In conclusion, HIV-1 related thrombocytopenia could have a multifaceted pathogenic mechanism (figure). Antiplatelet antibodies and circulating immune complexes could cause the consequent peripheral destruction in the spleen, liver, and bone marrow in that order; and, on the other hand, there would be ineffective immune thrombopoiesis and direct infection of the megakaryocytes, resulting in a change in the function and maturity of these cells.
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